(VIANEWS) – The Market ended the session with PHARMING GROUP (PHARM.AS) rising 22.35% to €1.22 on Monday, after three sequential sessions in a row of gains. AEX-Index rose 0.56% to €735.91, following the last session’s downward trend on what was a somewhat up trend trading session today.
About PHARMING GROUP
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Earnings Per Share
As for profitability, PHARMING GROUP has a trailing twelve months EPS of €0.048.
PE Ratio
PHARMING GROUP has a trailing twelve months price to earnings ratio of 25.38. Meaning, the purchaser of the share is investing €25.38 for every euro of annual earnings.
Volume
Today’s last reported volume for PHARMING GROUP is 40031500 which is 386.08% above its average volume of 8235460.
More news about PHARMING GROUP (PHARM.AS).
